logo Click here for the Chao Family Comprehensive Cancer Center Home Page Click here for the UC Irvine Home Page

Allen and Lee-Hwa Chao Lectureship in Cancer Research

The Chao Family Comprehensive Cancer Center's premiere annual event, the Allen and Lee-Hwa Chao Lectureship in Cancer Research, honors the late Hsi-Hsiung Chao by bringing internationally renowned leaders in the field of cancer research to UC Irvine to share insight, provoke thought and stimulate conversation about the myriad issues surrounding cancer. Serving both the campus and the wider community, speakers present two lectures, one tailored to a general audience (the Community Lecture) and the other to a technical audience (the Scientific Lecture).

Attendance is free, but registration is required for each lecture.

The 2016-17 Chao Lectureship presents:

Dr. James P. Allison photo

Dr. James P. Allison, PhD
Chair & Professor, Department of Immunology
Vivian L. Smith Distinguished Chair in Immunology
Executive Director, Immunotherapy Platform
Deputy Director, David H. Koch Center for Applied Research of Genitourinary Cancers
Associate Director, Center for Cancer Immunological Research
The University of Texas MD Anderson Cancer Center

Scientific Lecture

“Immune Checkpoint Blockade in Cancer Therapy: New Insights into Mechanisms”

5:00 p.m., Tuesday, Feb. 21, 2017
110 Tamkin Hall, UC Irvine Campus
RSVP by Feb 12 at https://goo.gl/forms/7C1t5f8HT5n3uAoY2

Community Lecture

“Immune Checkpoint Blockade in Cancer Therapy: New Insights and Prospects for Cures”

6 p.m., Wednesday, Feb. 22, 2017
Beckman Center, UC Irvine Campus
100 Academy Drive, Irvine, CA
Pre-lecture reception at 5 p.m.
RSVP by Feb. 12, 2017 to tori.bernatz@uci.edu or call 714-456-3729.

About the speaker

As an immunologist, Dr. James Allison’s fundamental discoveries include the definition of the structure of the T cell antigen receptor, demonstration that the T cell molecule CD28 provides costimulatory signals necessary for full T cells activation, and that the molecule CTLA-4 is an inhibitory checkpoint which inhibits activated T cells. He proposed that immune checkpoint blockade might be a powerful strategy for therapy of many cancer types, and conducted preclinical experiments showing its potential. He was involved in the development of ipilimumab, which was approved by the FDA for treatment of metastatic melanoma in 2011. His development of the concept of immune checkpoint blockade has transformed cancer therapy and saved thousands of lives.

Dr. Allison is a member of the National Academy of Sciences and the National Academy of Medicine. He has received numerous awards, including the Lifetime Achievement Award from the American Association of Immunologists, the Lloyd J. Old Award from the American Association for Cancer Research, the Novartis Award for Clinical Immunology, the Economist Magazine Innovation Prize for Biomedicine, the Breakthrough Prize in Biosciences, the Szent-Gyorgyi Prize for Progress in Cancer Research, and the Lasker-Debakey Clinical Medical Research Award.